• RG108 DNA Methyltransferase Inhibitor Workflow

  2026-08-15

  RG108 is a non-covalent DNA methyltransferase inhibitor for testing how methylation changes alter transcription, tumor suppressor gene reactivation, and cellular state. This practical guide connects biochemical potency with cell-based dosing, time-order experiments, orthogonal readouts, and troubleshooting.

• Chondrocyte-Targeted NAC Nanoparticles in Osteoarthritis

  2026-08-14

  The reference study developed chondroitin sulfate-modified PLGA nanoparticles to deliver N-acetylcysteine directly to chondrocytes, addressing the poor retention and limited local availability of free NAC in osteoarthritis. Its findings connect improved glutathione maintenance and GPX4 activity with reduced ferroptosis, cartilage degradation, and osteophyte formation, providing a mechanistic basis for targeted redox therapy.

• ORAI2-Driven SOCE in Salivary Fibrosis

  2026-08-14

  The reference study identifies ORAI2-mediated store-operated calcium entry as an early driver of postirradiation salivary gland fibrosis and maps a previously underdefined ORAI2/JNK/NFAT1/TGF-β1 signaling axis. Its combination of human samples, irradiated mouse glands, transcriptomics, pharmacologic perturbation, and functional saliva measurements provides a mechanistic framework for studying radiation-induced hyposalivation.

• (-)-JQ1 for BRD4 Negative-Control Workflows

  2026-08-13

  (-)-JQ1 is a cell-permeable, inactive JQ1 stereoisomer that helps separate BRD4-dependent effects from solvent, scaffold, and off-target artifacts. Use it beside active (+)-JQ1 and genetic BRD4 perturbation to strengthen epigenetics research, oxidative-stress assays, and cancer biology research.

• X-Gal Mechanism and Blue-White Screening

  2026-08-13

  X-Gal, also called 5-bromo-4-chloro-indolyl-β-D-galactopyranoside, is a chromogenic β-galactosidase substrate for visual clone selection. Its lacZα complementation readout supports blue-white colony screening in recombinant DNA technology, but it does not replace sequence confirmation.

• Dextrose (D-Glucose) in Tumor Immunometabolism

  2026-08-12

  Dextrose and D-glucose are not merely carbon sources: they are experimental variables that connect glycolysis, hypoxia, and immune-cell function. This guide translates tumor immunometabolism findings into practical assay design, reagent handling, and interpretation strategies.

• Live-Dead Bacterial Staining Kit Guide

  2026-08-12

  Learn how Live-Dead Bacterial Staining Kit SKU K2239 supports interpretable bacterial viability assays in antimicrobial, nanomaterial, and infection-model workflows. This scenario-based guide explains dye biology, controls, protocol standardization, data interpretation, and practical product selection.

• Anti-ROR1 Antibody Workflow for Translational Assays

  2026-08-11

  Build reproducible ROR1 binding, flow cytometry, and functional assay workflows with Zilovertamab, while keeping product-validated facts separate from optimization starting points. A mechanistic liver-injury study also shows how orthogonal mitochondrial, oxidative-stress, and pathway readouts can strengthen interpretation without implying untested cross-disease efficacy.

• Phosphatase Inhibitor Cocktail 2 in Chemoproteomics

  2026-08-11

  Phosphatase Inhibitor Cocktail 2 protects phosphorylation-dependent measurements from pre-analytic distortion. This guide connects phosphatase control with temperature-aware chemical proteomics and practical assay design.

• RG108 DNA Methyltransferase Inhibitor Workflow

  2026-08-10

  RG108 is a non-covalent DNA methyltransferase inhibitor for testing how methylation changes reshape gene expression in human cell models. This workflow separates biochemical potency from cellular response, combines methylation and phenotype readouts, and adapts assay-design lessons from recent mechanistic research without overstating antiviral or therapeutic applications.

• EZ Cap™ Cas9 mRNA (m1Ψ) and Editing Control

  2026-08-09

  EZ Cap™ Cas9 mRNA (m1Ψ) combines Cap1 capping, m1Ψ modification, and a poly(A) tail for controlled Cas9 expression. This article connects RNA architecture with temporal exposure, assay interpretation, and CRISPR-Cas9 precision decisions.

• LY2603618: Chk1 Inhibitor Research Guide

  2026-08-08

  LY2603618 is a selective Chk1 inhibitor that blocks ATP-site kinase activity and supports studies of DNA damage response, G2/M checkpoint control, and chemotherapy sensitization. Product information reports activity in lung and colon cancer models, while a 2024 HGSOC study provides a biomarker framework for interpreting CHK1 dependence.

• Annexin V-Cy5/DAPI Apoptosis Kit Guide

  2026-08-07

  The Annexin V-Cy5/DAPI Apoptosis Kit combines phosphatidylserine detection with DAPI membrane-integrity staining for rapid apoptosis and necrosis differentiation. The K2255 apoptosis detection kit supports fluorescence microscopy and flow cytometry within a product-reported 10–20-minute staining workflow.

• EZ Cap™ Cas9 mRNA (m1Ψ): Redefining Immune-Modulated Genome

  2026-08-07

  Explore how EZ Cap™ Cas9 mRNA (m1Ψ) leverages Cap1 structure and m1Ψ modification to optimize genome editing specificity and efficiency. This article uniquely analyzes immune modulation and assay design, bridging molecular engineering with translational research.

• Transforming mRNA Vaccine Design: Mechanisms and Strategic T

  2026-08-06

  This article bridges mechanistic insight and translational strategy for researchers advancing mRNA nanovaccine therapeutics, focusing on optimized ARCA-capped mRNA synthesis. It contextualizes the HyperScribe™ Co-transcription mRNA Synthesis Kit Plus (ARCA, T7) within the latest immunotherapy breakthroughs, especially in hepatocellular carcinoma, and provides actionable workflow guidance, protocol parameters, and forward-looking perspectives.

551 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page